Hemophagocytic lymphohistiocytosis secondary to epstein-barr virus reactivation in a patient with COVID-19

Hemophagocytic Lymphohistiocytosis (HLH) in coronavirus disease 2019 (COVID-19) is a recognized complication of severe illness. However, this phenomenon has been reported most often the setting acute infection. Here we present case patient with history respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection that subsequently developed HLH weeks after treatment COVID-19 and discharges from hospital. Upon re-admission, work-up demonstrated was experiencing Epstein-Barr virus (EBV) reactivation. As EBV known etiological trigger HLH, provides an alternative mechanism for seen patients who resolution symptomatology.